Regenexbio announces phases l/ll trial of RGX-202, a novel gene therapy candidate for Duchenne muscular dystrophy.

January 31, 2023 by Lizzie Deeble

Regenxbio has initiated Phase I/II AFFINITY DUCHENNE™ trial of RGX-202 and the company is also enrolling newly active observational screening study, AFFINITY BEYOND, evaluating AAV8 antibody prevalence in boys with Duchenne. Please read the full press release here.

Help Improve Understanding of Nutrition and Weight Management in DMD

Do you have 15 minutes and want to help improve our scientific understanding of the influence of nutrition and weight management in Duchenne muscular dystrophy? This is your chance to get involved and share your experience with researchers at the University of Glasgow and help contribute to better nutritional resources and guidelines for families and …

Welcoming Summer

Welcoming Summer It feels as though we have waited a while for warmer days this year and it is hard to believe that we are already over half way through 2024, and that the school year is coming to an end! As I write, I am aware of the additional challenge that long school holidays …

Fundraising Story – The Glasgow Kiltwalk for Action Duchenne

The Glasgow Kiltwalk for Action Duchenne Written by Sarah Kelly Last month my partner Paul and I took part in the Glasgow Kiltwalk to raise money for Action Duchenne. My little brother Jonathan has DMD, a couple of friends of ours were discussing doing the Kiltwalk and Paul had decided that he was going to …

Regenexbio announces phases l/ll trial of RGX-202, a novel gene therapy candidate for Duchenne muscular dystrophy.

Footer

Subscribe to our mailing list